iNFixion Bioscience announced today that it had been granted its second NIH Phase 1 SBIR Grant award from the National Institute of Neurological Disorders and Stroke (NINDS).  This 18-month grant, titled “Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency” is focused on identifying small molecule compounds that impact the rate of intracellular NF1 protein degradation.  This grant includes funding for an 18-month project that will be launched immediately, and includes continued collaboration with both the University of Wisconsin Biotechnology Center and Scripps Research in San Diego.

The core team at iNFixion Bioscience has successfully completed the prestigious NIH I-Corps™ commercialization program.  In addition to a commercialization curriculum, the program included teh requirement of conducting interviews with over 100 people from across the NF1 and Rare Drug ecosystems.  These interviews included: Adults with NF1, NF1 parents, NF clinic directors and specialists, rare disease and pharma professionals, and potential investment partners.  Using the I-Corps structure and methodology, the Infixion core team was able to crystallize its vision, improve their understanding of adult vs. pediatric requirements, establish a priority in terms of targeting NF1 symptoms, and solidify a tentative decision to pursue a companion biomarker program. The core team members also learned valuable presentation and teamwork skills while under the stress of conducting 106 half-hour interviews in just 7 weeks. 

To learn more about I-Corps™ click here:

iNFixion Bioscience has been awarded a NIH (NINDS) Phase 1 SBIR grant to pursue proof-of-principal research into studying the mechanisms and identifying drug compounds that impact transcriptional regulation of the NF1 gene. The grant aims include the development of a new NF1 reporter cell line, high throughput screening of multiple compound libraries, and the in vitro validation of compound hits on NF1 protein pathway effectors. With the announcement of this Phase 1 grant award, iNFixion Bioscience has hired its first full-time PhD scientist researcher (Dr. Michelle Mattson-Hoss, PhD) and has been accepted as a resident company at the prestigious San Diego JLABS innovation accelerator.  Hands-on laboratory experimentation is now underway.

To learn more about JLABS click here!


iNFixion Bioscience announced today its commitment to developing a new monoclonal antibody against NF1 protein. This NF1-specific reagent will be developed in rabbits using full-length NF1 protein as the immunogen, with the program goal being to establish a more sensitive and specific NF1 monoclonal antibody than is commercially available today. This NF1 research tool, once developed and validated, will be made available to the NF1 research community, on an at-cost basis.  This work is being developed in partnership with Abterra Biosciences (previously Digital Proteomics) and is financially supported by a partial grant from the NF Therapeutics Acceleration Program (NTAP).

The University of Wisconsin Biotechnology Center (UWBC) and iNFixion Bioscience have launched a multi-year collaboration to execute assay development and library screening focused on identifying small molecule NF1 transcriptional regulators.

iNFixion Bioscience announced ongoing collaborations with individual researchers from the University of Arizona, the University of Alabama Huntsville, and the Broad Institute in order to build tools to study NF1 haploinsufficiency.  These projects include developing machine learning models to identify compounds impacting NF1 gene expression and the development of synthetic transcription factors to specifically increase NF1 protein expression during in vitro experimentation.  These efforts are being supported in part by grants from NF Northeast and NF North Central, both regional members of NF Network, a national organization advocating for and supporting individuals and families impacted by Neurofibromatosis.